GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius SE & Co KGaA (OTCPK:FSNUY) » Definitions » Net Income From Continuing Operations

Fresenius SE KGaA (Fresenius SE KGaA) Net Income From Continuing Operations : $253 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Fresenius SE KGaA Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Fresenius SE KGaA's net income from continuing operations for the three months ended in Dec. 2023 was $-237 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $253 Mil.


Fresenius SE KGaA Net Income From Continuing Operations Historical Data

The historical data trend for Fresenius SE KGaA's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius SE KGaA Net Income From Continuing Operations Chart

Fresenius SE KGaA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,365.56 3,434.31 3,185.31 1,294.49 259.54

Fresenius SE KGaA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.40 495.72 179.85 -185.70 -236.64

Fresenius SE KGaA Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $253 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresenius SE KGaA (Fresenius SE KGaA) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals and fertility clinics in Germany, Spain, and Latin America. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.

Fresenius SE KGaA (Fresenius SE KGaA) Headlines

From GuruFocus

Top 1st-Quarter Trades of the Tweedy Browne Global Value Fund

By Margaret Moran Margaret Moran 04-13-2021

Tweedy Brown Comments on Fresenius

By Sydnee Gatewood Sydnee Gatewood 05-04-2021

Tweedy Browne Comments on Fresenius

By Sydnee Gatewood Sydnee Gatewood 06-01-2021

Tweedy Browne Fund's 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 05-04-2021